Phase 1 MSI-H Clinical Trials
9 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–9 of 9 trials
Recruiting
Phase 1Phase 2
A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.
Advanced Solid Tumors CancerMSI-H Cancer
Nimbus Wadjet, Inc.134 enrolled22 locationsNCT06898450
Recruiting
Phase 1
AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors
Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR)
Amgen464 enrolled6 locationsNCT07403721
Recruiting
Phase 1
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
Endometrial CancerAdvanced Solid TumorMetastatic Solid Tumor+1 more
MOMA Therapeutics132 enrolled14 locationsNCT06974110
Recruiting
Phase 1Phase 2
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
MelanomaAdvanced Solid TumorMetastasis+5 more
7 Hills Pharma, LLC126 enrolled5 locationsNCT06362369
Recruiting
Phase 1Phase 2
EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors
Endometrial CancerAdvanced Solid TumorsMSI-H or dMMR Advanced Solid Tumors+4 more
Eikon Therapeutics160 enrolled10 locationsNCT07262619
Recruiting
Phase 1
Intra-tumoral (IT) Injection of vvDD-hIL2-2-RG-1 for Metastatic Gastrointestinal and Peritoneal Tumors
Liver CancerEsophageal CancerGastric Cancer+9 more
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)18 enrolled1 locationNCT07001592
Active
Phase 1
A Randomized, Double Blind, Single-Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetic Profile of EIK1005 in Healthy Participants.
MSI-H Solid Tumors
EIKON Therapeutics, Inc.48 enrolled1 locationACTRN12625000334404
Recruiting
Phase 1Phase 2
Cadonilimab for PD-1/PD-L1 Blockade-refractory, MSI-H/dMMR, Advanced Colorectal Cancer
Colorectal Cancer Stage IVMismatch Repair-deficient (dMMR)Microsatellite Instability-high (MSI-H)
Sun Yat-sen University28 enrolled1 locationNCT05426005
Recruiting
Phase 1Phase 2
Sintilimab Plus Hypofractionated Radiotherapy for MSI-H/dMMR Rectal Cancer
Rectal CancerRadiotherapyAnti-PD-1 Antibody+2 more
West China Hospital20 enrolled1 locationNCT04636008